Cytokines potentiate human eosinophil superoxide generation in the presence of N(ω)-nitro-L-arginine methyl ester

International Journal of Immunopharmacology

Volumn 22, Issue 2, 2000, Pages 171-181

  Heiman, Ann S ^a   Allen Gipson, Diane ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Eosinophils; Interferon ; Nitric oxide inhibitors; Superoxide; Tumor necrosis factor

Indexed keywords

ARGININE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 8; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; PHORBOL 13 ACETATE 12 MYRISTATE; RANTES; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGY; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; EFFECTOR CELL; EOSINOPHIL; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL;

ARGININE; CELLS, CULTURED; CYTOKINES; DRUG SYNERGISM; ENZYME INHIBITORS; EOSINOPHILS; HUMANS; INTERFERON TYPE II; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; SUPEROXIDES; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033975721     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(99)00075-2     Document Type: Article

References (41)

1. Hogan S.P., Foster P.S. Cellular and molecular mechanisms involved in the regulation of eosinophil trafficking in vivo. Med. Res. Rev. 16:1996;407-432.
2. Boyce J.A. The pathobiology of eosinophilic inflammation. Allergy Asthma Proc. 18:1997;293-300.
3. Bartemes K.R., McKinney S., Gleich G.J., Kita H. Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG. J. Immunol. 162:1999;2982-2989.
4. Gleich G.J., Adolphson C.R., Leiferman K.M. The biology of the eosinophilic leukocyte. Annu. Rev. Med. 44:1993;85-101.
5. Horie S., Gleich G.J., Kita H. Cytokines directly induce degranulation and superoxide production from human eosinophils. J. Allergy Clin. Immunol. 98:1996;371-381.
6. Okada S., Hagan J.B., Kato M., Bankers-Fulbright J.L., Hunt L.W., et al. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J. Immunol. 160:1998;4010-4017.
7. Paul C.C., Tolbert M., Mahrer S., Singh A., Grace M.J. Cooperative effects of IL-3, IL-5 and GM- CSF: a new myeloid cell line inducible to eosinophils. Blood. 81:1993;1193-1199.
8. Kapp A., Zeck Kapp G., Czech W., Schopf E. The chemokine RANTES is more than a chemoattractant: characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF. J. Invest. Dermatol. 102:1994;906-914.
9. Alam R., Stafford S., Forsythe P., Harrison R., Faubion D., et al. RANTES is a chemotactic and activating factor for human eosinophils. J. Immunol. 150:1993;3442-3448.
10. Cain W.C., Stuart R.W., Lefkowitz D.L., Starnes J.D., Margolin S., et al. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int. J. Immunopharm. 20:1998;685-695.
11. Macari D.M., Teixeira M.M., Ansari T., Jeffery P.K., Hellewell P.G. Priming and induction of eosinophil trafficking in guinea-pig cutaneous inflammation by tumor necrosis factor alpha. Br. J. Pharmacol. 125:1998;1228-1235.
12. Slungaard A., Vercellotti G.M., Walker G., Nelson R.D., Jacob H.S. Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J. Exp. Med. 171:1990;2025-2041.
13. Fujisawa T., Abu Ghazaleh R., Kita H., Sanderson Cj, Gleich G.J. Regulatory effect of cytokines on eosinophil degranulation. J. Immunol. 144:1990;642-646.
14. Ishizuka T., Morita K., Hisada T., Ishizuka T., Ando S., et al. The direct effect of interferon-gamma on human eosinophilic leukemia cell lines; the induction of interleukin-5 mRNA and the presence of an interferon-gamma receptor. Inflammation. 20:1996;151-163.
15. Barnes P.J., Liew F.Y. Nitric oxide and asthmatic inflammation. Immunol Today. 16:1995;128-130.
16. Jatakanon A., Lim S., Kharitonov S.A., Chung K.F., Barnes P.J. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 53:1998;91-95.
17. Silvestri M., Spallarossa D., Yourukova V., Battistini E., Fregonese B., et al. Orally exhaled nitric oxide levels are related to the degree of blood eosinophilia in atopic children with mild-intermittent asthma. Eur. Respir. J. 13:1999;321-326.
18. Wang Y., Marsden P.A. Nitric oxide synthases: gene structure and regulation. Ignarro L., Murad F. Nitric oxide biochemistry, molecular biology and therapeutic implications. Adv. Pharmacol. 34:1995;71-90.
19. del Pozo V., de Arruda-Chaves E., de Andres B., Cardaba B., Lopez-Farre A., et al. Eosinophils transcribe and translate messenger RNA for inducible nitric oxide synthase. J. Immunol. 158:1997;859-864.
20. Wallerath T., Gath L., Aulitzky W.E., Pollack J.S., Kleinert H., et al. Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb. Haemost. 77:1997;163-167.
21. Miller R., Britigan B.E. The formation and biologic significance of phagocyte-derived oxidants. J. Invest. Med. 43:1995;39-49.
22. Carreras M., Poderoso J., Cadenas E., Boveris A. Measurement of nitric oxide and hydrogen peroxide production from human neutrophils. Packer L. Nitric oxide, physiological and pathological processes. Meth. Enzymol. 269:1996;65-75 Academic Press, New York.
23. Fukuyama N., Ichimori K., Su Z., Ishida H., Nakazawa H. Peroxynitrite formation from activated human leukocytes. Biochem. Biophys. Res. Commun. 224:1996;414-419.
24. Gagnon C., Leblond F.A., Fikep J.G. Peroxynitrite production by human neutrophils, monocytes and lymphocytes challenged with lipopolysaccharide. FEBS Lett. 431:1998;107-110.
25. Rohn T.T., Nelson L.K., Sipes K.M., Swain S.D., Jutila K.L., et al. Priming of human neutrophils by peroxynitrite: potential role in enhancement of the local inflammatory response. J. Leukoc. Biol. 65:1999;59-70.
26. Fishkoff S.A., Rossi R.M. Lineage directed HL-60 cell sublines as a model system for the study of early events in lineage determination of myeloid cells. Leukemia Res. 12:1990;679-686.
27. Fabian I., Lass M., Kletter Y., Golde D.W. Differentiation and functional activity of human eosinophilic cells from an eosinophil HL-60 subline: response to recombinant hematopoietic growth factors. Blood. 80:1992;788-794.
28. Heiman A.S., Hickman F., Ko D.-H., Lee H.J. New steroidal anti-inflammatory antedrugs bind to macrophage glucocorticoid receptors and inhibit nitric oxide generation. Steroids. 63:1998;644-649.
29. Horie S., Kita H. CD11b/CD18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant GM-CSF and PAF. J. Immunol. 152:1994;5457-5467.
30. Szabo C., Thiemermann C. Regulation of the expression of the inducible isoform of nitric oxide synthase. Ignarro L., Murad F. Nitric oxide, biochemistry, molecular biology and therapeutic implications. Advances in Pharmacology. 34:1995;113-153 Academic Press, New York.
31. Zanardo R., Costa E., Ferreira H., Antunes E., Martins A., et al. Pharmacological and immunohistochemical evidence for a functional nitric oxide synthase system in rat peritoneal eosinophils. Proc. Natl. Acad. Sci. USA. 95:1997;14111-14114.
32. Sadeghi-Hashjun G., Folkerts G., Henricks P., Verheyen A., van der Linde H., et al. Peroxynitrite induces airway hyperresponsiveness in guinea pigs in vitro and in vivo. Am. J. Respir. Crit. Care Med. 153:1996;1697-1701.
33. Crow J., Beckman J. Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Ignarro L., Murad F. Nitric oxide, biochemistry, molecular biology and therapeutic implications. Advances in Pharmacology. 34:1995;17-43 Academic Press, New York.
34. Malinsky T., Bailey F., Zhang Z., Chopp M. Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J. Cerebral Blood Flow Metab. 263:1993;355-358.
35. Zidek Z., Masek K. The behavior of nitric oxide within the immune system: illustrative review of conflicting data and their immunopharmacological aspects. Int. J. Immunopharm. 20:1998;319-343.
36. Freeman B.A., White C.R., Gutierrez H., Paler-Martinez A., Tarpey M.M., et al. Oxygen radical-nitric oxide reactions in vascular diseases. Ignarro L., Murad F. Nitric oxide biochemistry, molecular biology and therapeutic implications. Adv. Pharmacol. 34:1995;45-69.
37. Arock M., Le Goff L., Becherel P.-A., Dugas B., Debre P., et al. Involvement of FcεRII/CD23 and L-arginine dependent pathway in IgE-mediated activation of human eosinophils. Biochem. Biophys. Res. Commun. 203:1994;265-271.
38. Oliveira S., Fonseca S., Romao P., Figueiredo F., Ferreira S., et al. Microbicidal activity of eosinophils is associated with activation of the arginine-NO pathway. Parasite Immunol. 20:1998;405-412.
39. Ishizuka T., Mirota K., Hisada T., Ishizuka T., Ando S., et al. The direct effect of interferon-gamma on human eosinophilic leukemia cell lines: the induction of interleukin-5 mRNA and the presence of an interferon-gamma receptor. Inflammation. 20:1996;151-163.
40. Elsner J., Petering H., Hochstetter R., Kimmig D., Wells T.N., et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur. J. Immunol. 27:1997;2892-2898.
41. Zeck G., Czech W., Kapp A. TNF alpha-induced activation of eosinophil oxidative metabolism and morphology - comparison with IL-5. Exp. Dermatol. 3:1994;176-188.